瑞舒伐他汀联合瑞格列奈对老年2型糖尿病治疗效果观察  

Effect of rosuvastatin combined with repaglinide on elderly patients with type 2 diabetes mellitus

作　　者：崔国英 CUI Guo-ying(Liaoning Disabled Service Center,Shenyang 110015,China)

机构地区：[1]辽宁省残疾人服务中心,110015

出　　处：《中国现代药物应用》2021年第19期159-161,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析瑞舒伐他汀联合瑞格列奈对老年2型糖尿病的治疗效果。方法96例老年2型糖尿病患者,基于平行、单盲、随机对照设计原则,将所有患者分为对照组和观察组,每组48例。对照组给予瑞格列奈治疗,观察组在对照组基础上加服瑞舒伐他汀钙片治疗。比较两组患者治疗前后血糖、血脂、胰岛素。结果治疗后,观察组空腹血糖(FPG)(6.72±1.12)mmol/L、餐后2 h血糖(2 h PG)(7.35±1.13)mmol/L、糖化血红蛋白(HbA1c)(6.35±0.52)%均低于对照组的(7.50±1.35)mmol/L、(8.42±1.36)mmol/L、(8.20±0.64)%,差异均具有统计学意义(P<0.05)。治疗后,观察组总胆固醇(TC)为(1.02±0.61)mmol/L,甘油三酯(TG)为(4.05±0.31)mmol/L,低密度脂蛋白胆固醇(LDL-C)为(3.06±0.84)mmol/L,对照组TC为(1.81±0.52)mmol/L,TG为(4.93±0.45)mmol/L,LDL-C为(3.81±0.62)mmol/L。观察组TC、TG、LDL-C水平均低于对照组,差异均具有统计学意义(t=6.828、11.157、4.977,P<0.05)。治疗后,观察组空腹胰岛素(FIns)为(10.05±2.36)μU/ml,胰岛β细胞功能指数(HOMA-β)为(5.71±0.82),胰岛素抵抗指数(HOMA-IR)为(2.06±1.10),对照组FIns为(8.82±2.75)μU/ml,HOMA-β为(4.81±0.97),HOMA-IR为(2.86±1.15)。观察组FIns、HOMA-β高于对照组,HOMA-IR低于对照组,差异均具有统计学意义(t=2.352、4.909、3.483,P<0.05)。结论瑞舒伐他汀联合瑞格列奈治疗老年2型糖尿病,可有效降低血糖、血脂,缓解胰岛素抵抗现象,值得采纳及应用。Objective To analyze the therapeutic effect of rosuvastatin combined with repaglinide on elderly patients with type 2 diabetes mellitus.Methods A total of 96 elderly patients with type 2 diabetes mellitus were divided into control group and observation group based on parallel,single-blind,and randomized controlled design principles,with 48 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with repaglinide calcium tablets.The blood glucose,blood lipid and insulin before and after treatment were compared between the two groups.Results After treatment,the fasting plasma glucose(FPG)(6.72±1.12)mmol/L,2 h postprandial glucose(2 h PG)(7.35±1.13)mmol/L and glycosylated hemoglobin(HbA1c)(6.35±0.52)%of the observation group were lower than(7.50±1.35)mmol/L,(8.42±1.36) mmol/L and (8.20±0.64)% of the control group, and the difference was statistically significant (P<0.05). After treatment, the total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) of the observation group were (1.02±0.61), (4.05±0.31) and (3.06±0.84) mmol/L, which were (1.81±0.52), (4.93±0.45) and (3.81±0.62) mmol/L of the control group. The levels of TC, TG and LDL-C of the observation group were lower than those of the control group, and the difference was statistically significant (t=6.828, 11.157, 4.977;P<0.05). After treatment, the fasting insulin (FIns), homeostatic model assessment of β-cell function (HOMA-β), homeostatic model assessment for insulin resistance (HOMA-IR) of the observation group were (10.05±2.36) μU/ml, (5.71±0.82) and (2.06±1.10), which were (8.82±2.75) μU/ml, (4.81±0.97) and (2.86±1.15) of the control group. The FIns and HOMA-β of the observation group were lower than those of the control group, and HOMA-IR was lower than that of the control group, and the difference was statistically significant (t=2.352, 4.909, 3.483;P<0.05). Conclusion Combination of rosuvastatin and repaglinide can effectively reduce blood glucose,

关 键 词：瑞舒伐他汀 瑞格列奈 老年2型糖尿病 治疗效果 

分 类 号：R587.1[医药卫生—内分泌]